
"I saw a patient who's no longer a patient, and there's nothing better than that."
Where I see patients (1)
Selected research
-
Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells.
Blood
-
Cellular immunotherapy targeting CLL-1 for juvenile myelomonocytic leukemia.
Nature communications
-
In vivo validation of the palmitoylation cycle as a therapeutic target in NRAS-mutant cancer.
bioRxiv : the preprint server for biology
Clinical trials
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL...
Improvement in 5-year disease-free survival (DFS) with modified Berlin-Frankfurt-Münster (mBFM) chemotherapy without delayed intensification (DI) part 2 but with inotuzumab ozogamicin, versus full mBFM chemotherapy backbone includ...
Recruiting
More about this studyThe Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in...
The proportion will be calculated as the percent of eligible patients who are identified to have an a priori specified genomic or immunophenotypic target and who enroll on at least one of the sub-trials. The corresponding confiden...
Recruiting
More about this studyInotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or...
The response rate will be estimated using the proportion of eligible/evaluable patients with CR/CRi response. A one-sided lower 95% Agresti-Coull confidence limit will be calculated.
Recruiting
More about this studyContact me
Feeling at home
From bedside bingo to therapy dogs, we're here to help kids smile and feel more like themselves.
Visit Child Life services